Lucid Diagnostics Inc
NASDAQ:LUCD
Lucid Diagnostics Inc
Revenue
Lucid Diagnostics Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
Revenue
$4.3m
|
CAGR 3-Years
106%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Revenue
$20.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Revenue
$17.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
10%
|
CAGR 10-Years
9%
|
|
|
Stryker Corp
NYSE:SYK
|
Revenue
$22.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Revenue
$42.3B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Revenue
$8.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
15%
|
|
Lucid Diagnostics Inc
Glance View
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.
See Also
What is Lucid Diagnostics Inc's Revenue?
Revenue
4.3m
USD
Based on the financial report for Dec 31, 2024, Lucid Diagnostics Inc's Revenue amounts to 4.3m USD.
What is Lucid Diagnostics Inc's Revenue growth rate?
Revenue CAGR 3Y
106%
Over the last year, the Revenue growth was 79%. The average annual Revenue growth rates for Lucid Diagnostics Inc have been 106% over the past three years .
You don't have any saved screeners yet